ArticleNeurochemical research2026
Clinical Significance and Mechanistic Role of circLPAR3/miR-634 in Ischemic Stroke.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Individuals with hypertension carry a high risk of stroke, which endangers human health. The study systematically elucidated the dynamic expression, functional effects, and molecular mechanisms of the circular RNA LPAR3 in ischemic stroke (IS). 300 essential-hypertension (EH) patients were enrolled, comprising 165 cases diagnosed with IS. mRNA abundance was quantified via RT-qPCR. C57BL/6 mice treated with MACO and Neuro-2a cells receiving oxygen-glucose deprivation/reoxygenation (OGD/R) were applied for functional experiments. Neurological deficits and infarct volume of mice were evaluated. Besides, key cellular behaviors encompassing proliferative capacity, apoptotic rate, and inflammatory response were monitored. The putative binding event was interrogated through luciferase reporter and RIP coupled to qPCR assays. A diminished level of circLPAR3 was evidenced in the plasma of IS patients, which can distinguish IS cases from EH and remains an independent predictor of patients' poor prognosis. In vivo, overexpression of circLPAR3 alleviated MACO-mediated neurological deficit and cerebral infarction. In vitro, OGD/R triggered the surge in cell apoptosis and pro-inflammatory cytokine release, but it was attenuated by circLPAR3 upregulation. Mechanistically, the neuro-rescue driven by circLPAR3 was offset by miR-634, whose plasma expression was negatively correlated with circLPAR3. KLB expression was significantly downregulated in cellular models and co-regulated by circLPAR3 and miR-634. circLPAR3/miR-634 modulates the pathological progression of IS by directly regulating neuronal apoptosis and orchestrating inflammatory responses, and KLB may serve as a key downstream target mediating the biological functions.
Indexed as
Identifiers
42171873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.